ClinicalTrials.gg
CompletedNCT07277465MICROOBARUpdated Dec 18, 2025

Role of the Microbiota in Obesity: Effect After Bariatric Surgery

An interventional study of Bariatric surgery in Obese Patients With Bariatric Surgery, sponsored by Celia Bañuls. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Celia Bañuls · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Mar 2021, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Enrollment
237th of 332
60 · median 124
Started
2021
with 22 others
No phase
220 of 390
41 open now
Registered
336th of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 237th largest by enrollment of the 332 interventional ones that give a count, is one of 23 that started in 2021, is one of 220 with no phase, and was the 336th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

Several studies have demonstrated that bariatric surgery is effective for inducing weight loss in obese patients. In addition, the effects of this surgery on multiple associated alterations are well known, including changes in the secretion and activity of hormones involved in appetite regulation, satiety, and energy expenditure, as well as alterations in the gut microbiota composition.

However, in cases of severe obesity, recent data have challenged the prevailing view, as bacterial species associated with low microbial richness (prior to surgery) appear to change only marginally after bariatric surgery, despite significant metabolic improvements.

Our objective is to examine whether gut microbiota and gastrointestinal peptides are further impaired in severe obesity and, additionally, to explore how the microbiota relates to metabolic profile or sex, as well as whether bariatric surgery may differentially correct obesity-related intestinal microbial features.

To this end, we propose a prospective, interventional, translational clinical study involving a cohort of 60 obese patients (BMI > 35 kg/m²) undergoing laparoscopic gastric bypass surgery. Patients will be grouped according to their degree of obesity to assess potential baseline differences and to evaluate the efficacy of the intervention. Furthermore, we will investigate whether these parameters differ according to metabolic profile or sex.

Body composition and nutritional status will be assessed, along with cardiovascular risk factors and comorbidities (hypertension, obstructive sleep apnea syndrome, dyslipidemia, type 2 diabetes mellitus, and insulin resistance). Gastrointestinal hormones (ghrelin, GIP, GLP-1, PYY, CCK, and leptin) will be measured in serum using Luminex XMAP technology. The content and diversity of the gut microbiota will be analyzed (16S rRNA amplicon sequencing and shotgun metagenomic sequencing using Illumina MiSeq technology) in stool samples collected before and 6-12 months after surgery. Additionally, individualized dietary follow-up and assessment of participants' quality of life will be conducted.

Read the detailed description

Obesity and type 2 diabetes mellitus (T2DM) continue to increase worldwide and are strongly associated with adverse metabolic and cardiovascular outcomes. Bariatric surgery, particularly laparoscopic gastric bypass (LGB), remains the most effective therapeutic strategy for substantial weight reduction, glycemic improvement, and favorable modulation of gastrointestinal hormones, bile acids, and gut microbiota. Nevertheless, the mechanisms explaining heterogeneous metabolic responses-especially in individuals with severe, morbid, or extreme obesity-remain insufficiently elucidated. In particular, gut microbial diversity, microbial gene richness, and related inflammatory pathways appear to contribute to metabolic health, yet their behavior in severe obesity and their evolution following bariatric surgery remain poorly characterized.

To address these gaps, the investigators designed a prospective, interventional, comparative, and translational clinical study including 60 obese individuals scheduled for bariatric surgery at a single tertiary hospital. Participants will be consecutively recruited according to strict inclusion and exclusion criteria and classified by degree of adiposity (severe, morbid, or extreme obesity), metabolic phenotype (metabolically healthy or metabolically abnormal obesity), and sex.

Prior to the surgical intervention, a structured dietary protocol will be implemented. Participants will receive an individualized hypocaloric diet tailored to nutritional requirements, with a macronutrient distribution of 55% carbohydrates, 30% fats, and 15% proteins. During the two weeks preceding surgery, a very low-calorie diet based on Optisource® sachets will be administered in three daily intakes. Postoperative dietary progression will follow standardized clinical guidelines, with close monitoring to support weight reduction and metabolic stabilization. Follow-up evaluations will occur at 1, 6, and 12 months after surgery.

All participants will undergo comprehensive baseline and longitudinal assessments, including: evaluation of nutritional status; anthropometric measurements; body composition and basal metabolism; cardiovascular risk factors; metabolic comorbidities; and exclusion of secondary causes of obesity. Analytical parameters will include fasting plasma glucose, lipid profile (triglycerides, HDL-cholesterol), blood pressure, markers of hepatic and renal function, and additional biochemical indices relevant to obesity and T2DM risk stratification. Gut microbiota profiling will be conducted to evaluate microbial composition, diversity, and gene richness. Gastrointestinal hormone analyses will quantify circulating incretins and appetite-regulating peptides, including GLP-1, PYY, and ghrelin, to explore their association with postoperative metabolic outcomes. Oxidative stress and inflammatory parameters will be also assessed in order to stratify cardiovascular risk before and after induced weight loss after bariatric surgery.

Statistical analyses will be performed using SPSS 17.0. Categorical variables will be summarized with frequency distributions and percentages. Quantitative variables will be described using mean, range, and standard deviation, with normality assessed via the Kolmogorov-Smirnov test. Between-group comparisons (sex, metabolic phenotype) will employ unpaired t-tests or Mann-Whitney U tests; comparisons across obesity categories will use ANOVA. Longitudinal changes following surgery will be evaluated with repeated measures ANOVA or paired t-tests. Correlations will be analyzed using Pearson or Spearman methods, and logistic regression models will be developed to identify predictive factors for specific metabolic responses.

This study aims to determine whether gut microbiota alterations are directly linked to metabolic abnormalities across obesity phenotypes and whether bariatric surgery elicits differential microbial and hormonal responses according to degree of adiposity and sex. It further explores whether gastrointestinal peptides and other peripheral biomarkers can refine obesity phenotyping and enhance individualized clinical management.

03

Conditions studied

  • Obese Patients With Bariatric Surgery

Keywords

  • obesity
  • gut microbiota
  • metabolic syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a (BMI) greater than 40 kg/m² (or > 35 kg/m² with minimum one obesity comorbidity).
  • Aged between 18 and 65 years.
  • Patients with a known duration of obesity exceeding five years, despite dietary interventions and farmacological treatment.

Exclusion criteria

Exclusion Criteria:

  • Due to the nature of the study, patients with acute or chronic inflammatory diseases, established hepatic or renal insufficiency (defined as transaminase levels ±2 SD from the mean and estimated [CKD-EPI formula] >60), neoplasic diseases, or secondary causes of obesity (e.g., hypothyroidism, Cushing's syndrome) will be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Bariatric surgery in patients with obesity

    Patients will undergo bariatric surgery if they meet the inclusion criteria and are willing to participate in the study.

    Procedure: Bariatric surgery

Interventions

  • ProcedureBariatric surgery

    Bariatric surgery according to surgeon's assessment.

    Also known as: Roux en-Y bypass, sleeve gastrectomy, Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S)

06

What researchers measure

Primary outcomes

  1. Analyze the changes in the diversity of the intestinal microbiota after bariatric surgery.

    To assess the alpha-diversity of the intestinal microbiota, defined as the average diversity of species in an ecosystem, the Shannon index will be used. The results are interpreted as follows: values less than 2 are considered low in diversity and values greater than 3 are high in species diversity.

    Time frame: 5 years

  2. Assess differences in the diversity of the intestinal microbiota after bariatric surgery depending on the surgical procedure (Roux-en-Y gastric bypass vs sleeve gastrectomy vs SADI-S).

    To assess the beta-diversity of the intestinal microbiota, defined as the average diversity of species in an ecosystem, the Bray-Curtis index will be used. The results are interpreted as follows: values less than 2 are considered low in diversity and values greater than 3 are high in species diversity.

    Time frame: 5 years

Secondary outcomes

  1. Evaluate the differences in the diversity of the intestinal microbiota depending on whether patients present metabolically healthy obesity (MHO) or metabolically unhealthy obesity (MUHO) before surgery

    To asses the differences in alpha-diversity of the intestinal microbiota in both groups, it will be evaluated whether there are significant differences between the Shannon indices of the two groups. The classification of patients between MHO and MUHO will be carried out using the following criteria: MUHO will be considered when patients with obesity present ≥2 metabolic abnormalities, and MHO with ≤1 metabolic abnormalities; the following cardiovascular risk factors are considered metabolic abnormalities: elevated blood pressure (defined as either SBP ≥130 mm Hg, DBP ≥85 mm Hg, or treatment with antihypertensive medications), elevated triglycerides (as fasting triglyceride concentration ≥1.7 mmol/l), low HDL-C levels (defined as HDL-C \<1.04 mmol/l, in men, \<1.29 mmol/l/l in women, or treatment with lipid-lowering medications), dysglycemia (fasting plasma glucose 5.6 to 6.9 mmol/l, and/or and insulin resistance as HOMA-IR \>3.8).

    Time frame: 5 years

  2. Evaluate significant changes in body fat mass percentage after bariatric surgery.

    Percentage of body fat mass will be measured by bioelectrical impedance. It is considered to be high when ≥25% in men and ≥30% in women. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  3. Assess significant changes in high-sensitivity C-reactive protein (hs-CRP) as an inflammatory parameter after bariatric surgery.

    Participants will be considered to have achieved an improvement in high-sensitivity C-reactive protein levels if they normalize its value (normality values defined between 0 and 1.69mg/dl).

    Time frame: 3 years

  4. Evaluate significant changes in C3 protein as an inflammatory parameter after bariatric surgery.

    Participants will be considered to have achieved an improvement in C3 protein if they normalize its value (normality values defined between 81 and 157mg/dl).

    Time frame: 3 years

  5. Evaluate significant changes in interleukin 1-beta (IL-1B) levels as a pro-inflammatory molecule after bariatric surgery.

    IL-1B levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  6. Evaluate significant changes in interleukin 6 (IL-6) levels as a pro-inflammatory molecule after bariatric surgery.

    IL-6 levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  7. Evaluate significant changes in tumor necrosis factor alpha (TNF-alpha) levels as a pro-inflammatory molecule after bariatric surgery.

    TNF-alpha levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  8. Assess significant changes in superoxide dismutase (SOD) levels after bariatric surgery.

    Superoxide dismutase levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  9. Analyze the significant differences between metabolomic profile before and after bariatric surgery, and between different surgery procedures (Roux-en-Y gastric bypass vs. sleeve gastrectomy).

    NMR spectra will be used to obtain spectra from serum samples from the cohort. In order to evaluate if there will be significant differences after the dietetic intervention, a PLS-DA model for discrimination between basal and post intervention levels will be performed. Scores plots will be calculated with a 95% confidence interval.

    Time frame: 3 years

  10. Evaluate if there is a significant reduction after bariatric surgery in total ROS levels.

    Total ROS levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  11. Assess if there is a significant reduction after bariatric surgery in glutathione levels.

    Total glutathione levels will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  12. Analyze if there is a significant change after bariatric surgery in total free radicals levels.

    Total free radicals will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  13. Analyze if there is a significant reduction after bariatric surgery in mitochondrial ROS production.

    Mitochondrial ROS production will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  14. Evaluate if there is a significant change after bariatric surgery in superoxide levels.

    Superoxide content will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  15. Evaluate if there is a significant improvement after bariatric surgery in mitochondrial membrane potential.

    Mitochondrial membrane potential will be assessed by a flow cytometry assay. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  16. Identify and assess the differences in metabolic pathways of gut microbiota after bariatric surgery.

    Genetic markers of inflammation and metabolic pathways will be analyzed from the faeces samples, in order to identify different clusters of these pathways and determine the potential functions of gut microbiota. For that purpose, transcriptome will be quantified with nanostring techology. The relative quantity of gene expression (fold change) of each gene will be calculated with the comparative 2-ΔΔCT method, and significant differences will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 5 years

  17. Analyze if there is a significant reduction after the bariatric surgery in adipsin levels.

    Adipsin levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  18. Assess significant changes in plasmatic resistin levels as an inflammatory parameter after surgical intervention.

    Resistin levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  19. Analyze if there is a significant change after the bariatric surgery in leptin levels.

    Leptin will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  20. Evaluate significant reductions in Plasminogen activator inhibitor-1 (PAI-1) as an inflammatory parameter after the bariatric surgery.

    PAI-1 levels will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  21. Assess if there is a significant change after the bariatric surgery in ghrelin levels.

    Ghrelin will be measured using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  22. Assess significant changes in serum Glucagon-like peptide-1 (GLP-1) levels after the bariatric surgery.

    GLP-1 levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  23. Assess if there is a significant improvement after bariatric surgery in peptide YY (PYY) levels.

    PYY levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  24. Evaluate significant changes in serum gastric inhibitory polypeptide (GIP) levels after the bariatric surgery.

    GIP levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

  25. Analyze if there is a significant improvement after bariatric surgery in cholecystokinin (CCK) levels.

    CCK levels will be assessed using the Luminex® 200 analyzer system. A significant improvement will be considered when notable differences are observed in the mean values between groups measured through p-value (\<0.05) with a 95% confidence interval.

    Time frame: 3 years

07

Study locations

1 site
  • FISABIO
    Valencia, 46017, Spain
08

References and documents

Publications

  • Nijhawan S, Richards W, O'Hea MF, Audia JP, Alvarez DF. Bariatric surgery rapidly improves mitochondrial respiration in morbidly obese patients. Surg Endosc. 2013 Dec;27(12):4569-73. doi: 10.1007/s00464-013-3125-y. Epub 2013 Aug 24. PubMed 23982645 ↗
  • Akalestou E, Miras AD, Rutter GA, le Roux CW. Mechanisms of Weight Loss After Obesity Surgery. Endocr Rev. 2022 Jan 12;43(1):19-34. doi: 10.1210/endrev/bnab022. PubMed 34363458 ↗
  • Ciobarca D, Catoi AF, Copaescu C, Miere D, Crisan G. Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020 Jan 16;12(1):235. doi: 10.3390/nu12010235. PubMed 31963247 ↗
  • Cani PD, Van Hul M, Lefort C, Depommier C, Rastelli M, Everard A. Microbial regulation of organismal energy homeostasis. Nat Metab. 2019 Jan;1(1):34-46. doi: 10.1038/s42255-018-0017-4. Epub 2019 Jan 7. PubMed 32694818 ↗
  • Aron-Wisnewsky J, Prifti E, Belda E, Ichou F, Kayser BD, Dao MC, Verger EO, Hedjazi L, Bouillot JL, Chevallier JM, Pons N, Le Chatelier E, Levenez F, Ehrlich SD, Dore J, Zucker JD, Clement K. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 2019 Jan;68(1):70-82. doi: 10.1136/gutjnl-2018-316103. Epub 2018 Jun 13. PubMed 29899081 ↗
  • Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman JJGHM, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017 Oct 3;26(4):611-619.e6. doi: 10.1016/j.cmet.2017.09.008. PubMed 28978426 ↗
  • Sroka-Oleksiak A, Mlodzinska A, Bulanda M, Salamon D, Major P, Stanek M, Gosiewski T. Metagenomic Analysis of Duodenal Microbiota Reveals a Potential Biomarker of Dysbiosis in the Course of Obesity and Type 2 Diabetes: A Pilot Study. J Clin Med. 2020 Jan 29;9(2):369. doi: 10.3390/jcm9020369. PubMed 32013181 ↗
  • Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020 May 28;123(10):1127-1137. doi: 10.1017/S0007114520000380. Epub 2020 Feb 3. PubMed 32008579 ↗
  • Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. Gastroenterology. 2017 May;152(7):1671-1678. doi: 10.1053/j.gastro.2016.12.048. Epub 2017 Feb 10. PubMed 28192102 ↗
  • Haluzik M, Kratochvilova H, Haluzikova D, Mraz M. Gut as an emerging organ for the treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions. J Endocrinol. 2018 Apr;237(1):R1-R17. doi: 10.1530/JOE-17-0438. Epub 2018 Jan 29. PubMed 29378901 ↗
  • Murphy R, Clarke MG, Evennett NJ, John Robinson S, Lee Humphreys M, Hammodat H, Jones B, Kim DD, Cutfield R, Johnson MH, Plank LD, Booth MWC. Laparoscopic Sleeve Gastrectomy Versus Banded Roux-en-Y Gastric Bypass for Diabetes and Obesity: a Prospective Randomised Double-Blind Trial. Obes Surg. 2018 Feb;28(2):293-302. doi: 10.1007/s11695-017-2872-6. PubMed 28840525 ↗
  • Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018 Feb 13;71(6):670-687. doi: 10.1016/j.jacc.2017.12.014. PubMed 29420964 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2025, 46 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 11, 2025
StartActual
Mar 3, 2021
Primary completionActual
Jan 31, 2025
CompletionActual
May 31, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07277465
Lead sponsor
Celia Bañuls
Responsible party
Celia Bañuls (Principal Investigator, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana) — Sponsor-investigator
First posted
Dec 11, 2025
Start date
Mar 3, 2021
Primary completion
Jan 31, 2025
Completion
May 31, 2025
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion